Trump announces nine pharma giants commit to Most Favored Nation pricing for Medicaid and TrumpRx.gov direct sales; Sanofi blood thinner falls $750 to $16 with $150B US manufacturing boost., US News,

Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid for starting in 2026.

Nine drug manufacturers will offer their drugs to Medicaid recipients at most-favored-nation discounts in exchange for tariff exemptions.

Ten widely prescribed and expensive medications used by millions of Americans on Medicare to treat blood clots, cancer, heart disease and diabetes such as Xarelto, Eliquis and Jardiance will be getting a lot cheaper after negotiated discounts with ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. INDIANAPOLIS – Across the nation, consumers are dealing with the effects of prescription drug ...

Mark Cuban Cost Plus Drug is coming to TrumpRx, the federal initiative to offer Americans lower-cost prescriptions by buying drugs directly from manufacturers.

Today, ProPublica is launching Rx Inspector, a first-of-its-kind database that provides answers to what the FDA won’t tell us: where our generics are coming from and the track records of the factories that made them. The information is harder to find than you may think.

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "Not only are direct-to-consumer offerings more convenient," writes healthcare policy expert Sally Pipes, "they can ...

The commonwealth claims that pharmacy benefit managers and drug manufacturers are in cahoots to inflate insulin prices for Virginians artificially.